Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2010

01-03-2010

Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy

Author: Adi F. Gazdar

Published in: Cancer and Metastasis Reviews | Issue 1/2010

Login to get access

Abstract

Non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths in the USA and worldwide. Most patients present with advanced disease, and treatment options for these patients are generally limited to platinum-based chemotherapy and a few targeted therapies. Targeted agents currently in use for NSCLC inhibit oncogenic receptor tyrosine kinase pathways, such as the epidermal growth factor receptor (EGFR) pathway. While current EGFR-targeted agents, including erlotinib and gefitinib, may result in dramatic responses, they demonstrate efficacy in only a fraction of patients, and resistance to these agents frequently develops. In order to select patients most likely to benefit from blockade of EGFR pathways, investigators have focused on identifying molecular correlates of response to anti-EGFR therapy. New strategies to minimize the risk of resistance to EGFR inhibition have been employed in the development of next-generation EGFR tyrosine kinase inhibitors, such as PF00299804 and BIBW 2992; these include irreversibility of target binding, inhibition of multiple EGFR family receptors, and/or simultaneous inhibition of EGFR and other oncogenic pathways.
Literature
1.
2.
American Cancer Society. (2009). Cancer facts & figures, 2009. Atlanta, GA: American Cancer Society, Inc.
3.
4.
Breathnach, O. S., Freidlin, B., Conley, B., Green, M. R., Johnson, D. H., Gandara, D. R., et al. (2001). Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. Journal of Clinical Oncology, 19(6), 1734–1742.PubMed
5.
Carney, D. N. (2002). Lung cancer—time to move on from chemotherapy. New England Journal of Medicine, 346(2), 126–128.CrossRefPubMed
6.
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., et al. (2004). Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology, 22(11), 2184–2191.CrossRefPubMed
7.
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine, 355(24), 2542–2550.CrossRefPubMed
8.
Sibilia, M., Kroismayr, R., Lichtenberger, B. M., Natarajan, A., Hecking, M., & Holcmann, M. (2007). The epidermal growth factor receptor: from development to tumorigenesis. Differentiation, 75(9), 770–787.CrossRefPubMed
9.
10.
Hirsch, F. R., Varella-Garcia, M., & Cappuzzo, F. (2009). Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene, 28(Suppl 1), S32–S37.CrossRefPubMed
11.
Hirsch, F. R., Scagliotti, G. V., Langer, C. J., Varella-Garcia, M., & Franklin, W. A. (2003). Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer, 41(Suppl 1), S29–S42.CrossRefPubMed
12.
Gazdar, A. F. (2009). Personalized medicine and inhibition of EGFR signaling in lung cancer. New England Journal of Medicine, 361(10), 1018–1020.CrossRefPubMed
13.
Grandal, M. V., & Madshus, I. H. (2008). Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis. Journal of Cellular and Molecular Medicine, 12(5A), 1527–1534.CrossRefPubMed
14.
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008). Lung cancer. New England Journal of Medicine, 359(13), 1367–1380.CrossRefPubMed
15.
Ciardiello, F., & Tortora, G. (2008). EGFR antagonists in cancer treatment. New England Journal of Medicine, 358(11), 1160–1174.CrossRefPubMed
16.
Laskin, J. J., & Sandler, A. B. (2004). Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treatment Reviews, 30(1), 1–17.CrossRefPubMed
17.
Ho, C., & Laskin, J. (2009). EGFR-directed therapies to treat non-small-cell lung cancer. Expert Opinion on Investigational Drugs, 18(8), 1133–1145.CrossRefPubMed
18.
Solomon, B., Varella-Garcia, M., & Camidge, D. R. (2009). ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. Journal of Thoracic Oncology, 4(12), 1450–1454.PubMed
19.
Milano, A., De Iaffaioli, R. V., & Caponigro, F. (2007). Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy. Expert Opinion on Therapeutic Targets, 11(6), 771–782.CrossRefPubMed
20.
Quesnelle, K. M., Boehm, A. L., & Grandis, J. R. (2007). STAT-mediated EGFR signaling in cancer. Journal of Cellular Biochemistry, 102(2), 311–319.CrossRefPubMed
21.
Silva, C. M. (2004). Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene, 23(48), 8017–8023.CrossRefPubMed
22.
Modi, S., & Seidman, A. D. (2002). An update on epidermal growth factor receptor inhibitors. Current Oncology Reports, 4(1), 47–55.CrossRefPubMed
23.
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Jr., Di Maria, M. V., Veve, R., Bremmes, R. M., et al. (2003). Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. Journal of Clinical Oncology, 21(20), 3798–3807.CrossRefPubMed
24.
Ohsaki, Y., Tanno, S., Fujita, Y., Toyoshima, E., Fujiuchi, S., Nishigaki, Y., et al. (2000). Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncology Reports, 7(3), 603–607.PubMed
25.
John, T., Liu, G., & Tsao, M. S. (2009). Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene, 28(Suppl 1), S14–S23.CrossRefPubMed
26.
Eberhard, D. A., Giaccone, G., & Johnson, B. E. (2008). Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. Journal of Clinical Oncology, 26(6), 983–994.CrossRefPubMed
27.
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Jr., Franklin, W. A., Dziadziuszko, R., Thatcher, N., et al. (2006). Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 24(31), 5034–5042.CrossRefPubMed
28.
Parra, H. S., Cavina, R., Latteri, F., Zucali, P. A., Campagnoli, E., Morenghi, E., et al. (2004). Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non–small-cell lung cancer. British Journal of Cancer, 91(2), 208–212.PubMed
29.
Perez-Soler, R., Chachoua, A., Hammond, L. A., Rowinsky, E. K., Huberman, M., Karp, D., et al. (2004). Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. Journal of Clinical Oncology, 22(16), 3238–3247.CrossRefPubMed
30.
Tsao, M. S., Sakurada, A., Cutz, J. C., Zhu, C. Q., Kamel-Reid, S., Squire, J., et al. (2005). Erlotinib in lung cancer—molecular and clinical predictors of outcome. New England Journal of Medicine, 353(2), 133–144.CrossRefPubMed
31.
Rego, R. L., Foster, N. R., Smyrk, T. C., Le, M., O'Connell, M. J., Sargent, D. J., et al. (2010). Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. British Journal of Cancer, 102, 165–172.CrossRefPubMed
32.
Isola, J., Tanner, M., Forsyth, A., Cooke, T. G., Watters, A. D., & Bartlett, J. M. (2004). Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clinical Cancer Research, 10(14), 4793–4798.CrossRefPubMed
33.
Zhu, C. Q., da Cunha, S. G., Ding, K., Sakurada, A., Cutz, J. C., Liu, N., et al. (2008). Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 26(26), 4268–4275.CrossRefPubMed
34.
Hirsch, F. R., Herbst, R. S., Olsen, C., Chansky, K., Crowley, J., Kelly, K., et al. (2008). Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. Journal of Clinical Oncology, 26(20), 3351–3357.CrossRefPubMed
35.
Hirsch, F. R., Varella-Garcia, M., Cappuzzo, F., McCoy, J., Bemis, L., Xavier, A. C., et al. (2007). Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 18(4), 752–760.CrossRefPubMed
36.
Dziadziuszko, R., Witta, S. E., Cappuzzo, F., Park, S., Tanaka, K., Danenberg, P. V., et al. (2006). Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clinical Cancer Research, 12(10), 3078–3084.CrossRefPubMed
37.
Gandhi, J., Zhang, J., Xie, Y., Soh, J., Shigematsu, H., Zhang, W., et al. (2009). Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE, 4(2), e4576.CrossRefPubMed
38.
Bell, D. W., Lynch, T. J., Haserlat, S. M., Harris, P. L., Okimoto, R. A., Brannigan, B. W., et al. (2005). Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology, 23(31), 8081–8092.CrossRefPubMed
39.
Dziadziuszko, R., Holm, B., Skov, B. G., Osterlind, K., Sellers, M. V., Franklin, W. A., et al. (2007). Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Annals of Oncology, 18(3), 447–452.CrossRefPubMed
40.
Takano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., et al. (2005). Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. Journal of Clinical Oncology, 23(28), 6829–6837.CrossRefPubMed
41.
Gazdar, A. F. (2009). Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 28(Suppl 1), S24–S31.CrossRefPubMed
42.
Costa, D. B., Kobayashi, S., Tenen, D. G., & Huberman, M. S. (2007). Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer, 58(1), 95–103.CrossRefPubMed
43.
Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N., et al. (2006). Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. Journal of Clinical Oncology, 24(21), 3340–3346.CrossRefPubMed
44.
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350(21), 2129–2139.CrossRefPubMed
45.
Miller, V. A., Riely, G. J., Zakowski, M. F., Li, A. R., Patel, J. D., Heelan, R. T., et al. (2008). Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. Journal of Clinical Oncology, 26(9), 1472–1478.CrossRefPubMed
46.
Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497–1500.CrossRefPubMed
47.
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., et al. (2004). EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 101(36), 13306–13311.CrossRefPubMed
48.
Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Janne, P. A., et al. (2008). First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Journal of Clinical Oncology, 26(15), 2442–2449.CrossRefPubMed
49.
Tamura, K., Okamoto, I., Kashii, T., Negoro, S., Hirashima, T., Kudoh, S., et al. (2008). Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). British Journal of Cancer, 98(5), 907–914.CrossRefPubMed
50.
Taron, M., Ichinose, Y., Rosell, R., Mok, T., Massuti, B., Zamora, L., et al. (2005). Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clinical Cancer Research, 11(16), 5878–5885.CrossRefPubMed
51.
Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947–957.CrossRefPubMed
52.
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., et al. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. New England Journal of Medicine, 361(10), 958–967.CrossRefPubMed
53.
Greulich, H., Chen, T. H., Feng, W., Janne, P. A., Alvarez, J. V., Zappaterra, M., et al. (2005). Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Medicine, 2(11), e313.CrossRefPubMed
54.
Molina-Vila, M. A., Bertran-Alamillo, J., Reguart, N., Taron, M., Castella, E., Llatjos, M., et al. (2008). A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. Journal of Thoracic Oncology, 3(11), 1224–1235.CrossRefPubMed
55.
56.
Mack, P. C., Holland, W. S., Burich, R. A., Sangha, R., Solis, L. J., Li, Y., et al. (2009). EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. Journal of Thoracic Oncology, 4(12), 1466–1472.PubMed
57.
Zhang, X., & Chang, A. (2008). Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. International Journal of Medical Sciences, 5(4), 209–217.PubMed
58.
Ladanyi, M., & Pao, W. (2008). Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Modern Pathology, 21(Suppl 2), S16–S22.CrossRefPubMed
59.
Hynes, N. E., & Lane, H. A. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer, 5(5), 341–354.CrossRefPubMed
60.
Mendelsohn, J., & Baselga, J. (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. Journal of Clinical Oncology, 21(14), 2787–2799.CrossRefPubMed
61.
Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., et al. (2008). Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. Journal of Clinical Oncology, 26(15), 2450–2456.CrossRefPubMed
62.
Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., De Rosa, F., et al. (2007). Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. Journal of Clinical Oncology, 25(12), 1545–1552.CrossRefPubMed
63.
Pirker, R., Pereira, J. R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., et al. (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 373(9674), 1525–1531.CrossRefPubMed
64.
65.
Thatcher, N., Chang, A., Parikh, P., Rodrigues, P. J., Ciuleanu, T., von Pawel J., et al. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366(9496), 1527–1537.CrossRefPubMed
66.
Shepherd, F. A., Rodrigues, P. J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine, 353(2), 123–132.CrossRefPubMed
67.
Tarceva® (erlotinib) tablets, oral [package insert]. Melville, NY: OSI Pharmaceuticals Inc. (2009).
68.
Kobayashi, S., Boggon, T. J., Dayaram, T., Janne, P. A., Kocher, O., Meyerson, M., et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 352(8), 786–792.CrossRefPubMed
69.
Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., et al. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clinical Cancer Research, 12(19), 5764–5769.CrossRefPubMed
70.
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Medicine, 2(3), e73.CrossRefPubMed
71.
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., et al. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Journal of Clinical Oncology, 23(25), 5900–5909.CrossRefPubMed
72.
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., et al. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Medicine, 2(1), e17.CrossRefPubMed
73.
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical Cancer Research, 12(21), 6494–6501.CrossRefPubMed
74.
Suda, K., Onozato, R., Yatabe, Y., & Mitsudomi, T. (2009). EGFR T790M mutation: a double role in lung cancer cell survival? Journal of Thoracic Oncology, 4(1), 1–4.PubMed
75.
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., et al. (2008). Detection of mutations in EGFR in circulating lung-cancer cells. New England Journal of Medicine, 359(4), 366–377.CrossRefPubMed
76.
Bean, J., Brennan, C., Shih, J. Y., Riely, G., Viale, A., Wang, L., et al. (2007). MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 104(52), 20932–20937.CrossRefPubMed
77.
Aita, M., Fasola, G., Defferrari, C., Brianti, A., Bello, M. G., Follador, A., et al. (2008). Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 68(3), 183–196.CrossRefPubMed
78.
Alvarez, R. H., Kantarjian, H. M., & Cortes, J. E. (2006). Biology of platelet-derived growth factor and its involvement in disease. Mayo Clinic Proceedings, 81(9), 1241–1257.CrossRefPubMed
79.
Guix, M., Faber, A. C., Wang, S. E., Olivares, M. G., Song, Y., Qu, S., et al. (2008). Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. Journal of Clinical Investigation, 118(7), 2609–2619.PubMed
80.
Kono, S. A., Marshall, M. E., Ware, K. E., & Heasley, L. E. (2009). The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resistance Updates, 12(4–5), 95–102.CrossRefPubMed
81.
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., et al. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proceedings of the National Academy of Sciences of the United States of America, 102(21), 7665–7670.CrossRefPubMed
82.
Burris, H. A., III. (2009). Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene, 28(Suppl 1), S4–S13.CrossRefPubMed
83.
Britten, C. D. (2004). Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Molecular Cancer Therapeutics, 3(10), 1335–1342.PubMed
84.
Yang, C.-H., Shih, J.-Y., Su, W.-C., Hsia, T.-C., Ho, C.-L., Dudek, A. Z., et al. (2009). BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaïve patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). Journal of Thoracic Oncology, 4(9 suppl 1), S294–S295. Abstract A3.3.
85.
Xu, H., Yu, Y., Marciniak, D., Rishi, A. K., Sarkar, F. H., Kucuk, O., et al. (2005). Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Molecular Cancer Therapeutics, 4(3), 435–442.PubMed
86.
Ye, D., Mendelsohn, J., & Fan, Z. (1999). Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene, 18(3), 731–738.CrossRefPubMed
87.
Shih, J.-Y., Yang, C.-H., Su, W.-C., Hsia, T.-C., Tsia, C.-M., Chen, Y.-M., et al. (2009). A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 TKI, in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2). Journal of Clinical Oncology, 27(suppl), 15S. Abstract 8013.
88.
Eskens, F. A., Mom, C. H., Planting, A. S., Gietema, J. A., Amelsberg, A., Huisman, H., et al. (2008). A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. British Journal of Cancer, 98(1), 80–85.CrossRefPubMed
89.
Yang, C.-H., Shih, J.-Y., Su, W.-C., Hsia, T.-C., Ho, C.-L., Dudek, A. Z., et al. BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaïve patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). Oral presentation at: 13th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; July 31-August 4, 2009; San Francisco, CA.
90.
Shih, J.-Y., Yang, C.-H., Su, W.-C., Hsia, T.-C., Tsai, C.-M., Chen, Y.-M., et al. A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 TKI, in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2). Poster presented at: 45th Annual Meeting of the American Society of Clinical Oncology; May 29-June 2, 2009; Orlando, FL.
91.
Yang, C.-H., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR (HER1) and HER2 + BSC versus placebo + BSC in patients with non-small cell lung cancer failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1): a preliminary report. Poster presented at: 45th Annual Meeting of the American Society of Clinical Oncology; May 29-June 2, 2009; Orlando, FL.
92.
Janne, P. A., Reckamp, K., Koczywas, M., Camidge, D. R., Engelman, J. A., Khuri, F., et al. (2009). A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results. Journal of Thoracic Oncology, 4(9 suppl 1), S293–S294. Abstract A3.1.
93.
Natale, R. B., Thongprasert, S., Greco, F. A., et al. (2009). Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). Journal of Clinical Oncology, 27 (suppl), Abstract 8009.
94.
De Boer, R., Arrieta, O., Gottfried, M., et al. (2009). Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). Journal of Clinical Oncology, 27(suppl), 409s Abstract 8010.
95.
Herbst, R. S., Sun, Y., Korfee, S., et al. (2009). Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advance non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). Journal of Clinical Oncology, 27(suppl), 807s Abstract CRA8003.
96.
Bahleda, R., Soria, J. C., Harbison, C. T., et al. (2009). Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. Journal of Clinical Oncology, 27(suppl), 431s Abstract 8098.
97.
Shannon, A. M., Telfer, B. A., Smith, P. D., Babur, M., Logie, A., Wilkinson, R. W., et al. (2009). The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts. Clinical Cancer Research, 15(21), 6619–6629.CrossRefPubMed
98.
Friday, B. B., Yu, C., Dy, G. K., Smith, P. D., Wang, L., Thibodeau, S. N., et al. (2008). BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Research, 68(15), 6145–6153.CrossRefPubMed
99.
Barrett, S. D., Bridges, A. J., Dudley, D. T., Saltiel, A. R., Fergus, J. H., Flamme, C. M., et al. (2008). The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorganic & Medicinal Chemistry Letters, 18(24), 6501–6504.CrossRef
100.
Gridelli, C., Maione, P., & Rossi, A. (2008). The potential role of mTOR inhibitors in non-small cell lung cancer. The Oncologist, 13(2), 139–147.CrossRefPubMed
101.
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., et al. (2008). Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. Journal of Clinical Oncology, 26(3), 361–367.CrossRefPubMed
102.
Wu, P., Liu, T., & Hu, Y. (2009). PI3K inhibitors for cancer therapy: what has been achieved so far? Current Medicinal Chemistry, 16(8), 916–930.CrossRefPubMed
103.
Oh, Y., Herbst, R. S., Burris, H., Cleverly, A., Musib, L., Lahn, M., et al. (2008). Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. Journal of Clinical Oncology, 26(7), 1135–1141.CrossRefPubMed
104.
Villalona-Calero, M. A., Ritch, P., Figueroa, J. A., Otterson, G. A., Belt, R., Dow, E., et al. (2004). A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clinical Cancer Research, 10(18 Pt 1), 6086–6093.CrossRefPubMed
105.
Baselga, J., Rojo, F., Dumez, H. (2005). Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: a pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen. Journal of Clinical Oncology, 23. Abstract 3028.
106.
Rizvi, N. A., Kris, M. G., Miller, V. A. (2008). Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: results from phase 2. Journal of Clinical Oncology, 26. Abstract 8053.
107.
Yoshimura, N., Kudoh, S., Kimura, T., Mitsuoka, S., Matsuura, K., Hirata, K., et al. (2006). EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer, 51(3), 363–368.CrossRefPubMed
108.
Suzuki, T., Fujii, A., Ohya, J., Amano, Y., Kitano, Y., Abe, D., et al. (2007). Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. Cancer Science, 98(12), 1977–1984.CrossRefPubMed
109.
Gratacap, M. P., Martin, V., Valera, M. C., Allart, S., Garcia, C., Sie, P., et al. (2009). The new tyrosine-kinase inhibitor and anti-cancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood, 114(9), 1884–1892.CrossRefPubMed
110.
Natale, R. B., Bodkin, D., Govindan, R., Sleckman, B. G., Rizvi, N. A., Capo, A., et al. (2009). Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. Journal of Clinical Oncology, 27(15), 2523–2529.CrossRefPubMed
111.
Pirker, R., Szczesna, A., von Pawel, J., et al. (2008). FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology, 26. Abstract 3.
Metadata
Title
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy
Author
Adi F. Gazdar
Publication date
01-03-2010
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-010-9201-z

Other articles of this Issue 1/2010

Cancer and Metastasis Reviews 1/2010 Go to the issue

OriginalPaper

Natural history of bronchial preinvasive lesions

NON-THEMATIC REVIEW

Cetuximab in combination therapy: from bench to clinic

OriginalPaper

Lung cancer: From single-gene methylation to methylome profiling

NON-THEMATIC REVIEW

The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment

OriginalPaper

Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy

OriginalPaper

microRNAs and lung cancer: tumors and 22-mers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits